ADMA Biologics (NASDAQ:ADMA) Upgrade of Rating
ADMA Biologics (NASDAQ:ADMA)’s stock was upped to “Outperform” by equity research analysts at Raymond James. ADMA’s “Mkt Perform” rating is no longer valid.
The rating upgrade is well received by investors, as NASDAQ:ADMA is now trading 10.89% higher at $2.75 as of 2:06 AM New York time. ADMA Biologics’s stock is 0% in the past 200 days. It has underperformed the S&P 500 Index, which has increased 6.00% in the same time.
Aisling Capital Llc had the largest stake with ownership of 3.61M shares as of q2 2015 for 5.39% of the fund’s portfolio. Consonance Capital Management Lp is another bullish investment manager who is owning 1.27M shares of ADMA Biologics or 0.89% of their fund’s portfolio. Furthermore, Broadfin Capital Llc have 0.72% of their fund’s portfolio invested in the company for 1.11M shares. The New York-based fund Iguana Healthcare Management Llc revealed it had bought so far a stake worth about 0.39% of the investment manager’s stock portfolio in ADMA Biologics. The New York-based fund Perceptive Advisors Llc is also positive about the stock, possessing 150,000 shares or 0.34% of their fund’s portfolio.
ADMA Biologics (NASDAQ:ADMA) Profile
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate.
ADMA Biologics (NASDAQ:ADMA) traded up 10.89% on 14 November, hitting $2.75. A total of 187,302 shares of the company’s stock traded hands. This is up from average of 118,533 shares. ADMA Biologics has a 52 week low of $2.01 and a 52 week high of $6.88. The company has a market cap of $70.93 million and a P/E ratio of 0.
Get the latest ADMA Biologics (NASDAQ:ADMA) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.